Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5067725 | 0.87 | HTT (0.57) | LMNAPOLBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2187506 | 0.85 | HTT (0.59) | LMNAPOLBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17729939 | 0.81 | HTT (0.61) | LMNAPOLBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL27684818 | 0.78 | CHRNB2 (0.50) | LMNAPOLBSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3955220 | 0.77 | SMN1; SMN2 (0.71) | LMNAPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4224936 | 0.75 | SMN1; SMN2 (0.46) | LMNAPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6367774 | 0.75 | SMN1; SMN2 (0.51) | LMNAPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL11126939 | 0.74 | SMN1; SMN2 (0.50) | LMNAPOLBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3223229 | 0.73 | SMN1; SMN2 (0.54) | LMNAPOLBSMN1; SMN2ALDH1A1CYP2D6 | |
| SCHEMBL3996738 | 0.73 | TSHR (0.73) | LMNASMN1; SMN2CYP3A4CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051386-A1 | Tricyclic Pyrazole Derivatives as Cannabinoid Receptor Modulators | CADILA HEALTHCARE LIMITED (IN) | 2008-02-28 | — | — | US | claimed |
| EP-1781668-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LTD. (IN) | 2007-05-09 | — | — | EP | claimed |
| WO-2006025069-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2006-03-09 | — | — | WO | claimed |
| US-20080051386-A1 | Tricyclic Pyrazole Derivatives as Cannabinoid Receptor Modulators | CADILA HEALTHCARE LIMITED (IN) | 2008-02-28 | — | — | US | disclosed |
| EP-1781668-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LTD. (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006025069-A2 | TRICYCLIC PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CADILA HEALTHCARE LIMITED (IN) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051386-A1 | Tricyclic Pyrazole Derivatives as Cannabinoid Receptor Modulators | CNR2, CNR1, GPR55 | LMNA 4462/4885POLB 4356/4885KDM4E 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.